Pro-Active Dasatinib Dose Reduction Based on Trough Levels May Minimise Toxicity and Preserve Efficacy - Interim Analysis of the ALLG CML 12 Direct StudyDavid T Yeung, On Behalf of the ALLG, Deborah L. White et al.|Blood|2019Cited by 3
P720: PROACTIVE DASATINIB DOSE REDUCTION IN THE ALLG CML 12 DIRECT STUDY BASED ON TROUGH LEVELS MINIMISE TOXICITY AND PRESERVE EFFICACYDavid T Yeung, Timothy P. Hughes, Andrew Grigg et al.|HemaSphere|2022Cited by 1